141 related articles for article (PubMed ID: 32125178)
21. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
Diabetes Obes Metab; 2024 Feb; 26(2):540-547. PubMed ID: 37880868
[TBL] [Abstract][Full Text] [Related]
22. A review of the pharmacological properties of insulin degludec and their clinical relevance.
Haahr H; Heise T
Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
[TBL] [Abstract][Full Text] [Related]
23. Design of non-standard insulin analogs for the treatment of diabetes mellitus.
Pandyarajan V; Weiss MA
Curr Diab Rep; 2012 Dec; 12(6):697-704. PubMed ID: 22983891
[TBL] [Abstract][Full Text] [Related]
24. Generation of post-meal insulin correction boluses in type 1 diabetes simulation models for in-silico clinical trials: More realistic scenarios obtained using a decision tree approach.
Camerlingo N; Vettoretti M; Del Favero S; Facchinetti A; Choudhary P; Sparacino G;
Comput Methods Programs Biomed; 2022 Jun; 221():106862. PubMed ID: 35597208
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy outcomes in women with type 1 diabetes using insulin degludec: response to Kamran et al.
Ringholm L; Do NC; Damm P; Mathiesen ER
Acta Diabetol; 2023 Jan; 60(1):141-142. PubMed ID: 36283987
[No Abstract] [Full Text] [Related]
26. Insulin degludec: pharmacokinetics in patients with renal impairment.
Kiss I; Arold G; Roepstorff C; Bøttcher SG; Klim S; Haahr H
Clin Pharmacokinet; 2014 Feb; 53(2):175-83. PubMed ID: 24163264
[TBL] [Abstract][Full Text] [Related]
27. Advances in newer basal and bolus insulins: impact on type 1 diabetes.
Vliebergh J; Lefever E; Mathieu C
Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):1-7. PubMed ID: 33315628
[TBL] [Abstract][Full Text] [Related]
28. An Insulin Bolus Advisor for Type 1 Diabetes Using Deep Reinforcement Learning.
Zhu T; Li K; Kuang L; Herrero P; Georgiou P
Sensors (Basel); 2020 Sep; 20(18):. PubMed ID: 32899979
[TBL] [Abstract][Full Text] [Related]
29. Current Status of Weekly Insulin Analogs and Their Pharmacokinetic/Pharmacodynamic Evaluation by the Euglycemic Clamp Technique.
An N; Wang X; He A; Chen W
Clin Pharmacol Drug Dev; 2023 Sep; 12(9):849-855. PubMed ID: 37439495
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database.
Rossi MC; Bonfanti R; Graziano G; Larosa M; Lombardo F; Nicolucci A; Vespasiani G; Zucchini S; Rabbone I;
Acta Diabetol; 2024 May; ():. PubMed ID: 38789610
[TBL] [Abstract][Full Text] [Related]
31. A Personalized and Adaptive Insulin Bolus Calculator Based on Double Deep Q- Learning to Improve Type 1 Diabetes Management.
Noaro G; Zhu T; Cappon G; Facchinetti A; Georgiou P
IEEE J Biomed Health Inform; 2023 May; 27(5):2536-2544. PubMed ID: 37027579
[TBL] [Abstract][Full Text] [Related]
32. Short- and Long-Term Effects on Glucose Control of Nonadherence to Insulin Therapy in People With Type 2 Diabetes An
Visentin R; Cobelli C; Sieber J; Dalla Man C
J Diabetes Sci Technol; 2024 Mar; 18(2):309-317. PubMed ID: 38284154
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Glucose Metrics in Adults with Type 1 Diabetes Switching to Insulin Glargine 300 U/mL: A Retrospective, Propensity-Score Matched Study.
Charleer S; Fieuws S; De Block C; Bolsens N; Nobels F; Mikkelsen K; Mathieu C; Gillard P
Diabetes Technol Ther; 2024 Mar; ():. PubMed ID: 38386438
[No Abstract] [Full Text] [Related]
34. Offline reinforcement learning for safer blood glucose control in people with type 1 diabetes.
Emerson H; Guy M; McConville R
J Biomed Inform; 2023 Jun; 142():104376. PubMed ID: 37149275
[TBL] [Abstract][Full Text] [Related]
35. A Reinforcement Learning Based System for Blood Glucose Control without Carbohydrate Estimation in Type 1 Diabetes: In Silico Validation.
Hettiarachchi C; Malagutti N; Nolan C; Daskalaki E; Suominen H
Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():950-956. PubMed ID: 36086458
[TBL] [Abstract][Full Text] [Related]
36. A strategy based on integer programming for optimal dosing and timing of preventive hypoglycemic treatments in type 1 diabetes management.
Pavan J; Noaro G; Facchinetti A; Salvagnin D; Sparacino G; Del Favero S
Comput Methods Programs Biomed; 2024 Jun; 250():108179. PubMed ID: 38642427
[TBL] [Abstract][Full Text] [Related]
37. Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations.
Deerochanawong C; Bajpai S; Dwipayana IMP; Hussein Z; Mabunay MA; Rosales R; Tsai ST; Tsang MW
Diabetes Ther; 2017 Dec; 8(6):1197-1214. PubMed ID: 29094298
[TBL] [Abstract][Full Text] [Related]
38. A physical activity-intensity driven glycemic model for type 1 diabetes.
Hobbs N; Samadi S; Rashid M; Shahidehpour A; Askari MR; Park M; Quinn L; Cinar A
Comput Methods Programs Biomed; 2022 Nov; 226():107153. PubMed ID: 36183639
[TBL] [Abstract][Full Text] [Related]
39. Time-Action Profile of Technosphere Insulin in Children with Type 1 Diabetes.
Haller MJ; Jones MC; Bhavsar S; Kaiserman KB
Diabetes Ther; 2023 Mar; 14(3):611-617. PubMed ID: 36652106
[TBL] [Abstract][Full Text] [Related]
40. ReplayBG: A Digital Twin-Based Methodology to Identify a Personalized Model From Type 1 Diabetes Data and Simulate Glucose Concentrations to Assess Alternative Therapies.
Cappon G; Vettoretti M; Sparacino G; Favero SD; Facchinetti A
IEEE Trans Biomed Eng; 2023 Nov; 70(11):3227-3238. PubMed ID: 37368794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
